What Is the Fair Value of Eli Lilly and Company (LLY) Stock? Intrinsic Value Analysis

July 2026

Eli Lilly and Company (LLY) has transformed from a steady, traditional pharmaceutical giant into one of the most valuable companies in the world, driven by the explosive growth of its GLP-1 incretin franchise (Mounjaro and Zepbound). With trailing twelve-month (TTM) revenues surpassing $86 billion and a market capitalization exceeding $1 trillion, investors are grappling with a critical question: Is the stock’s premium valuation justified by its unprecedented growth, or has the market priced in a flawless future?

This article breaks down the fair value of LLY stock using multiple valuation methodologies, including Discounted Cash Flow (DCF), P/E multiples, PEG ratio, EV/EBITDA, and the Dividend Discount Model (DDM).

Quick Answer

Based on a composite of multiple valuation models, the estimated fair value of Eli Lilly (LLY) stock in July 2026 is approximately $950 to $1,050 per share. With the stock trading at elevated multiples (around 42x trailing earnings) and consensus price targets near $1,345, LLY appears moderately overvalued to fairly valued depending on the duration of its hyper-growth phase. While the underlying business fundamentals are spectacular, the current stock price leaves little margin of safety for pricing pressures or pipeline setbacks.

Current Stock Price & Valuation

As of July 2026, Eli Lilly's financial profile reflects a company operating at peak performance:

  • Market Capitalization: ~$1.06 Trillion
  • LTM Revenue: $86.46 Billion
  • LTM Net Income: $27.58 Billion
  • LTM Diluted EPS: $30.81
  • Trailing P/E Ratio: ~41.8x
  • Forward P/E Ratio: ~26x (based on 2026 EPS guidance of $35.50 - $36.50)
  • LTM Revenue Growth: 47%
  • Gross Margin: 81.9% (Q1 2026)
  • Operating Margin: 47%

Lilly's valuation is a stark contrast to its peers. While Pfizer trades at roughly 18.6x earnings and Johnson & Johnson at 29.5x, Lilly commands a 41.8x trailing multiple. The market is paying a massive premium for Lilly's 47% revenue growth, compared to the single-digit growth of its competitors.

Detailed Analysis

To determine the intrinsic value of LLY, we must look at several valuation frameworks.

1. Discounted Cash Flow (DCF) Analysis

The DCF model estimates the present value of Lilly's future free cash flows (FCF).

  • Revenue Growth: Analysts project 30.8% growth in 2026, 16.5% in 2027, and 12.7% in 2028. We assume a 15% CAGR over the next 5 years, tapering to 5% in years 6-10.
  • FCF Margin: Currently at 14.35% due to heavy reinvestment in manufacturing and R&D. We project this to expand to 25% as capital expenditures normalize and high-margin GLP-1 sales scale.
  • Discount Rate (WACC): 8.5% (reflecting a higher cost of capital but a strong, wide-moat pharmaceutical business).
  • Terminal Growth Rate: 2.5% (in line with long-term GDP growth).

Calculation: Discounting the projected cash flows and terminal value yields an intrinsic value of approximately $900 to $980 per share. (Note: Morningstar's independent DCF model also assigns a fair value estimate of $900 per share).

2. P/E Multiple Analysis

Lilly's management recently raised 2026 non-GAAP EPS guidance to $35.50 - $36.50.

  • If we apply a normalized, premium pharmaceutical forward P/E multiple of 30x to the midpoint of 2026 earnings ($36.00), the fair value is $1,080.
  • If the market sustains its current hyper-growth multiple of 35x forward earnings, the implied price is $1,260.

3. PEG Ratio Analysis

The Price/Earnings-to-Growth (PEG) ratio helps contextualize the high P/E.

  • Forward P/E: 26x
  • Expected Earnings Growth (Next 3 Years): ~29% annualized (46.4% in 2026, 27% in 2027, 16% in 2028).
  • PEG Ratio: 26 / 29 = 0.89

A PEG ratio below 1.0 typically suggests a stock is undervalued relative to its growth. However, because pharmaceutical growth rates can decelerate sharply due to patent cliffs or pricing pressures, a PEG of 0.89 indicates the stock is fairly valued for its current growth cycle.

4. EV/EBITDA Valuation

  • Enterprise Value (EV): ~$1.1 Trillion (Market Cap + $43B Debt - Cash)
  • LTM EBITDA: ~$38 Billion
  • EV/EBITDA Multiple: ~28.9x

A 28.9x EV/EBITDA multiple is exceptionally high for a mature pharmaceutical company, reflecting the market's expectation that EBITDA will double over the next few years. If EBITDA normalizes to $60 billion by 2028 and trades at a 15x multiple, the implied Enterprise Value would be $900 billion, suggesting downside risk if growth stalls.

5. Dividend Discount Model (DDM)

Lilly pays a growing dividend, recently increased by 15% to an annualized rate of $6.92 per share for 2026.

  • Expected Dividend: $6.92
  • Cost of Equity: 8.5%
  • Long-Term Dividend Growth Rate: 7.5% (aggressive, but supported by massive cash flow growth).
  • DDM Value: $6.92 / (0.085 - 0.075) = $692 per share.

The DDM significantly undervalues LLY because the company returns capital primarily through growth reinvestment and share repurchases ($4.1 billion in 2025) rather than just dividends.

Bull Case

The bull case for Eli Lilly centers on the continued dominance of the GLP-1 franchise. Mounjaro and Zepbound generated $12.8 billion in Q1 2026 alone. If Lilly successfully expands indications for these drugs (e.g., cardiovascular outcomes, sleep apnea) and launches its oral GLP-1 effectively, revenue could easily exceed $100 billion by 2027. Furthermore, the company's operating margins are staggering—guided to hit 49.0% to 50.5% for 2026. If Lilly maintains this efficiency, earnings will compound rapidly, easily justifying analyst price targets of $1,345+.

Bear Case

The bear case focuses on valuation and pricing power. In Q2 2026, Lilly reported a 60% increase in volume, but this was partially offset by a 13% decrease in realized prices. As competition from Novo Nordisk and new entrants intensifies, and as insurance payers push back on costs, price erosion could accelerate. Additionally, Lilly carries $43 billion in debt from aggressive acquisitions and manufacturing buildouts. If demand normalizes or a safety scare occurs, the 42x trailing P/E multiple will contract violently, potentially sending the stock back to the $700 - $800 range.

Key Metrics Summary

MetricLLY Current Data (July 2026)Peer Average (PFE, JNJ, MRK)
Trailing P/E41.8x~27x
LTM Revenue Growth47%4%
Operating Margin47%24%
ROIC41.83%~15%
Dividend Yield~0.6%~3.5%

Frequently Asked Questions

Why is Eli Lilly's P/E ratio so much higher than Pfizer or Johnson & Johnson?

Lilly's premium valuation is driven by its growth rate. In the last twelve months, Lilly's revenue grew 47%, compared to 1.4% for Pfizer and 7.9% for J&J. Investors are paying for Lilly's future earnings potential, specifically the explosive demand for its weight-loss and diabetes drugs, Mounjaro and Zepbound.

Is Eli Lilly's debt a concern?

Lilly's total debt has climbed to roughly $43 billion as of mid-2026, up from $14 billion in 2017. While this is a large nominal figure, it is manageable. The debt was used to fund strategic acquisitions (Verve, Ajax, Orna) and massive manufacturing capacity. With an operating margin of 47% and LTM net income of $27.5 billion, Lilly has ample cash flow to service this debt.

How does price erosion affect LLY's fair value?

Price erosion is the biggest threat to Lilly's intrinsic value. In Q2 2026, realized prices fell 13% globally. Currently, massive volume growth (60% in Q2) is masking this price drop. However, if volume growth slows down as the market saturates, falling prices will compress gross margins (currently 81.9%), which would directly lower the company's discounted cash flow valuation.

What is Morningstar's fair value estimate for LLY?

As of late July 2026, Morningstar assigns Eli Lilly a fair value estimate of $900.00 per share, carrying a 2-star rating, indicating they believe the stock is moderately overvalued at current market prices.

Final Verdict

Eli Lilly is arguably the highest-quality operator in the pharmaceutical sector today, boasting peer-crushing revenue growth, expanding ROIC (41.83%), and a dominant product pipeline. However, at a trailing P/E of 41.8x and a market cap over $1 trillion, the stock is priced for perfection.

Based on our blended valuation analysis—anchored by a DCF value of ~$900-$980 and a forward earnings multiple value of ~$1,080—the fair intrinsic value of LLY stock is between $950 and $1,050.

Therefore, at current trading levels, Eli Lilly stock is moderately overvalued. While momentum and earnings beats could continue to drive the stock toward consensus targets of $1,345, value-conscious investors may want to wait for a broader market pullback or a multiple contraction before initiating a new position.

Ready to Analyze Your Next Investment?

Get a free AI-powered fair value analysis on any stock. See intrinsic value, margin of safety, and institutional-grade risk metrics in seconds. No credit card required.

Want full access to our institutional research tools? Explore Invest Daily Pro.

Put This Into Practice

You're reading about dividend safety. But is YOUR dividend actually safe?

Our AI analyzes payout ratio trends, free cash flow coverage, balance sheet risk, and dividend growth history to give every stock a Fortress Score from 0–100.

Watch: Related Videos

from Invest Daily
Watch: I Built an AI That Values Any Stock in 30 Seconds (Full Demo)
YouTube
Watch: $3 TRILLION Gone in One Day… What Happens to Stocks This Week?
YouTube

Get This Analysis in Your Inbox Every Morning

Get our daily market briefing with institutional-grade analysis, key developments, and actionable strategy - delivered before the opening bell.